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ABSTRACT
Background: A significant number of melanoma patients experience recurrence 
to distant sites, despite having had surgical treatment of the primary lesion, with 
curative intent. Monitoring of patients for early evidence of disease recurrence 
would significantly improve management of the disease, allowing timely therapeutic 
intervention. Circulating tumor DNA (ctDNA) is becoming a well-recognized biomarker 
for monitoring malignancies and has, in a few studies, been shown to signify disease 
recurrence earlier than conventional methods. 
Methods: We performed a retrospective analysis of plasma ctDNA using droplet 
digital PCR (ddPCR) in 30 primary melanoma patients with tumors harboring BRAF, 
NRAS or TERT promoter mutations. Mutant specific ctDNA, measured during clinical 
disease course, was compared with disease status in patients with confirmed disease 
recurrence (n = 3) and in those with no evidence of disease recurrence (n = 27).
Results: Mutant specific ctDNA was detected in all three patients with disease 
recurrence at the time of clinically confirmed progression. In one case, plasma ctDNA 
detection preceded clinical identification of recurrence by an interval of 4 months. 
CtDNA was not detected in patients who were asymptomatic and had no radiological 
evidence of recurrence. 
Conclusions: This study demonstrates promising results for the use of ctDNA 
as an informative monitoring tool for melanoma patients having undergone tumor 
resection of an early stage primary tumor. The clinical utility of ctDNA for monitoring 
disease recurrence warrants investigation in prospective studies as it may improve 
patient outcome.
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INTRODUCTION
Whilst the majority of melanoma patients are cured 
by surgical resection, approximately 30% of patients 
will present with systemic recurrence at some point 
during their lifetime [1], sometimes 10 or more years 
after diagnosis of primary melanoma [2–7]. Numerous 
factors such as clinical staging as well as host and tumor-
dependent variables have been associated with recurrence 
[1, 7, 8]. Such characteristics however are not infallible 
and do not account for all patients that present with 
recurrence [4]. The risk of melanoma recurrence therefore 
is never entirely eliminated and the ability to correctly 
identify a subset of patients at risk of recurrence from a 
patient population with an expected favorable outcome is 
therefore challenging. 
Timely detection of recurrence is of significant 
importance for improved patient outcomes given that 
surgical removal of solitary or a small number of 
isolated metastases most often improves overall survival 
[9–11]. Moreover, it has recently been shown that 
metastatic melanoma patients are more likely to achieve 
a long lasting response to systemic therapy when it is 
administered to patients with a low burden of disease 
[12, 13]. Currently, sentinel lymph node biopsies (SLNB), 
physical examination and radiological imaging methods 
such as 18F-FDG PET/CT are employed to stage primary 
melanomas and detect metastatic disease. Whilst 18F-FDG 
PET/CT provides valuable information on the location and 
metabolic activity of metastatic disease through real-time 
whole-body imaging [14], such imaging is not routinely 
used in the follow-up of early stage patients (American 
Joint Committee on Cancer (AJCC) stages 0-IIA) but 
rather for staging symptomatic patients or monitoring 
high-risk patients [15]. SLNBs are occasionally 
recommended for staging purposes for those with ≥1 mm 
thick melanomas [16]. However, they are relatively 
invasive and prohibitively costly for ongoing routine 
monitoring [17, 18]. Consequently, physical examination 
(including lymph node palpation) and radiological 
assessments are the primary surveillance strategies for 
patients having undergone primary tumor resection [15]. 
There is however, little consensus on the frequency 
of clinical assessment; the National Comprehensive 
Cancer Network (NCCN) guidelines suggest physical 
examinations be conducted every 3 to 12 months for the 
first 5 years and then annually thereafter for AJCC stage 
IA-IIA, and every 3 to 6 months for 2 years, then every 3 
to 12 months for 3 years followed by annual checks and 
optional imaging for stages IIB to IV [15]. Importantly, 
physical examinations are usually inefficient at detecting 
distant metastases (disease that has spread to other sites 
such as lung, liver, bone or brain) [17], and thus melanoma 
recurrence is often detected at a late stage. Thus, there 
remains a need to improve follow-up for early detection 
of melanoma recurrence, which could lead to timely 
interventions and earlier treatment options that may 
improve patient outcomes. 
CtDNA is an easily accessible marker that may 
be suitable for routine monitoring of disease recurrence 
[18–22]. The exact mechanism of ctDNA production 
remains elusive but it is thought to be released from cells 
predominantly by apoptosis and possibly through active 
secretion [23, 24]. Recent studies show that ctDNA levels 
exhibit a close correlation with disease status in a number 
of different cancers including gastric [25], colorectal [26], 
colon [27] and breast [19, 28], although, most studies have 
been conducted in the metastatic setting where ctDNA 
is likely to be relatively abundant. A few studies have 
demonstrated a potential utility for detecting ctDNA post-
surgery in early stage cancers [29]. The presence of ctDNA 
was found to correlate with minimal residual disease in 
breast [28] and colon [27] cancers, and provide an early 
measure of clinically detectable recurrence in early stage 
lung cancer [30]. 
While there is now growing evidence that ctDNA 
has the potential to detect disease recurrence earlier or at 
the same time as conventional methods [27, 28, 30–32], 
the use of ctDNA for monitoring of residual disease and 
recurrence in clinically disease-free patients remains 
limited [27, 30, 31]. Thus, it remains unclear whether 
ctDNA is detectable at early stages and/or can provide 
early evidence of disease progression. 
In this study, we aimed to determine whether in 
melanoma, ctDNA could indicate the presence of disease 
recurrence and/or of metastatic disease, earlier than 
conventional methods. To do this, we analyzed BRAF, 
NRAS and TERT promoter mutant ctDNA using serial 
blood samples from melanoma patients with and without 
confirmed disease recurrence.
RESULTS 
Patient samples and cohort summary
From the original cohort of 139 patients, we 
selected 3 patients who developed metastatic disease 
and 27 patients with no evidence of disease recurrence 
at last follow-up or at the time of unrelated death for 
retrospective analysis (Figures 1 and 2). The median age 
was 63.7 (range 28 to 92 years). The median time from 
primary melanoma resection to enrolment was 14.7 
months (range 0 to 134.6 months) and the median follow-
up was 22 months (range 5.9 to 48.8 months). 
Nineteen patients harbored a BRAF mutation, 
V600E (n = 8), V600K (n = 10) or K601E (n = 1); 
4 patients had NRAS mutations, Q61K (n = 3), Q12D 
(n = 1); 13 had TERT promoter mutations, C228T 
(n = 8), C250T (n = 5) and 10 patients had more than 
one mutation. Of the patients that presented with disease 
recurrence, patient 2 harbored the BRAF K601E mutation, 
patient 6 harbored NRAS Q12D and TERT C228T 
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mutations and patient 23 harbored the BRAF V600E 
mutation. Patient characteristics and their mutation status 
are described in Table 1. 
Quantification of mutant specific ctDNA from 
plasma
Overall, cfDNA was isolated from 73 plasma 
samples taken from 30 patients. The number of mutant 
ctDNA copies per mL of plasma was quantified by ddPCR. 
CtDNA was measurable in all 3 patients (Figure 3) 
that presented with disease recurrence and in none of those 
without recurrence at last follow-up.
Patient 2 
Curative resection was performed for a primary 
nodular melanoma located on the neck with a Breslow 
measurement of 8.35mm. PET/CT and SLNB conducted 
immediately after resection revealed no regional or 
distant metastases. The patient was disease free for 
approximately five years, then presented with two 
positive lymph node (LN) metastases at 302 weeks 
and with one positive LN at 432 weeks after primary 
diagnosis. All positive LNs were resected at time of 
identification. Approximately 36 weeks after the last 
resection the patient was recruited into this study at which 
time ctDNA was not detected (Figure 3A). 13 weeks later 
(48 weeks post lymph node dissection (LND)), PET/CT 
revealed no evidence of metastases and ctDNA remained 
negative. Following an investigative colonoscopy one-
year post LND and 9 weeks post negative PET/CT, a 
subsequent biopsy revealed stage IV melanoma with 
bowel metastasis at which time ctDNA was detected at 3 
copies/mL of plasma. A subsequent PET/CT also revealed 
bone metastases. The patient commenced full dose 
combination Ipilimumab/Nivolumab therapy and within 
three weeks, ctDNA was undetectable. At last follow-up 
(week 503), the patient had no evidence of metastatic 
disease on PET/CT. 
Patient 6 
Patient 6 underwent curative resection for a 1.1 mm 
primary melanoma on the right anterior scalp, with a 
mitotic rate of 2/sq. mm but no ulceration, regression, 
perineural or lymphovascular invasion. Re-excision was 
performed at week 3. At week 12 the patient was recruited 
Figure 1: Overview of patient enrolment, sample collection and analysis. CtDNA was detectable in all three patients with 
disease recurrence but not in patients with no evidence of disease recurrence.
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into the study and ctDNA was not detected (Figure 3B). 
Approximately 30 weeks following initial diagnosis, a 
second primary invasive melanoma on the scalp measuring 
3.1 mm with vascular involvement was excised with a 
wide margin. At week 62, ctDNA was not detected, but 
clinical and radiological evaluation three weeks later 
revealed a level III cervical lymph node (which was 
confirmed as metastatic melanoma on pathology) and five 
FDG avid nodules in the right lung (largest measuring 
6 mm). No blood was collected at this time. Prior to 
commencing treatment of pembrolizumab almost eight 
weeks later, NRAS Q12D mutant ctDNA was detected at 
1.4 copies/mL of blood. Within 3 weeks of commencing 
treatment, ctDNA was undetectable. Following PET/
CT at week 84 post initial diagnosis, a significant but 
incomplete improvement was observed when compared to 
the previous PET/CT scan and ctDNA was not detected. 
The patient subsequently showed complete response on 
PET/CT and eighteen months post treatment cessation, 
remains disease free. The TERT promoter mutation found 
in the tumor, was not detected in plasma at any time point 
in this patient.
Patient 23
In 2004, the patient underwent resective surgery for 
a primary nodular melanoma on the left thigh. Histology 
reported the melanoma contained an unusual polypoidal 
appearance however demonstrated invasion of the reticular 
dermis (Clark level 4) and a maximum thickness of 1.82 
mm. The lesion extended to within 1mm of a lateral 
resection margin and hence further wide local excision was 
recommended. Re-excision was completed within 3 weeks 
with no further residual tumor identified. There was at least 
10 mm of skin and subcutaneous fat at either edge of the 
scar. Nodules of metastatic melanoma were identified and 
excised from the dermis and subcutis within and adjacent 
to the scar site 494 weeks after the primary melanoma 
was identified. Excision was complete with clearance of 
0.5 mm from the deep and side margins. At week 577 the 
patient was recruited into the study and ctDNA was not 
detected (Figure 3C). Abdominal ultrasound at week 615 
showed no evidence of metastatic disease. Approximately 
42 weeks later at week 619, the patient presented with 
a red, painful eye and ocular melanoma was found. The 
patient elected to undergo enucleation. We did not have a 
blood sample to test ctDNA at this time point. Histological 
and molecular analysis of the tumor indicated the presence 
of a BRAF V600E mutation. BRAF V600E mutant ctDNA 
was detected at 6.4 copies/mL of plasma at week 626, and 
again at week 635 at 5.1 copies/mL of plasma. Having 
refused PET/CT scans due to claustrophobia, the patient 
underwent a gastroscopy for anemia at week 642, which 
revealed a 4 cm gastric metastasis and 2 ileum metastases 
(10 cm apart). All metastases were surgically removed 
following confirmation of metastatic melanoma on biopsy. 
Histological and molecular analysis of the gastric tumor 
also indicated the presence of a BRAF V600E mutation. 
No blood samples were collected at this time. At week 
652 PET/CT revealed progressive disease with bone 
metastases. At this time, ctDNA was detected at 6.3 copies 
per mL of plasma and combination therapy of dabrafenib 
and trametinib was commenced. CtDNA levels declined 
to 1.6 copies/ml at 6 weeks and were undetectable at 
10 weeks post treatment commencement. At week 667 
(14 weeks post treatment initiation), PET/CT revealed 
complete response which has persisted and ctDNA levels 
have remained undetectable.
Figure 2: Swimmers plot in months from diagnosis of first primary melanoma to last follow-up. A total of 30 patients 
were assessed in the study. Bar colors indicate the melanoma stage at enrolment. All patients had a blood sample drawn at enrolment (zero 
months) and at the time points indicated (black dots). Three patients experienced recurrence during study follow up (red line) and another 
three cases died from reasons unrelated to melanoma (blue triangle). 
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1 F 38 I Unclassified 0.35 - - Yes BRAF V600E
2 M 50 III Nodular 8.3 Incipient 4 No BRAF K601E
3 M 90 II SSM 3.7 Yes 10 No TERT C228T
4 M 83 I SSM 1 No 1 Slight BRAF V600E, 
NRAS Q61K, TERT 
C228T
5 M 93 III - - - - - TERT C228T
6 M 81 I Unclassified 1.1 No No No NRAS Q12D, 
TERT C228T
7 M 75 I CBD 1.2 No No Yes NRAS Q61K, TERT 
C250T
8 F 28 I SSM 0.38 No <1 No BRAF V600E
9 M 46 I SSM 0.45 No No Yes BRAF V600K
10 M 89 II Nodular 5.5 No 6 - BRAF V600K, 
TERT C250T
11 F 92 I SSM 0.3 No No No BRAF V600K
12 F 45 I Unclassified 0.3 - - No BRAF V600K
13 M 38 I SSM 0.3 No No No BRAF V600E
14 M 41 0 - - - - - TERT C228T
15 M 73 III - - - - - BRAF V600K, 
TERT C250T
16 M 58 II SSM 7 No No No NRAS Q61K
17 M 56 0 - - - - - BRAF V600E
18 M 58 III - - - - - NRAS Q61K, TERT 
C228T
29 M 44 II SSM 1 Yes Active No TERT C250T
20 F 43 I Unclassified 0.5 No No No BRAF V600K
21 M 67 II Nodular 25 Yes 5 No BRAF V600E, 
TERT C228T
22 M 74 II Nodular 2 Yes 10 Yes BRAF V600E, 
TERT C250T
23 M 62 I Nodular 1.82 - 20 - BRAF V600E
24 M 75 II Lentigo 2.1 No 8 Yes BRAF V600K
25 M 90 III - - - - - BRAF V600K
26 M 88 II SSM 0.4 - - Yes TERT C228T
27 M 69 I SSM 0.4 No No No BRAF V600K
28 M 58 I SSM 0.45 No No Yes BRAF V600K
29 F 68 I Unclassified 0.3 - - Yes BRAF V600E
30 M 40 I Unclassified 0.45 - - Yes BRAF V600E
Abbreviations: SSM = Superficial spreading melanoma; CBD = cannot be determined; – = unavailable. *Assessed by 
ddPCR
Patients 2, 6 and 23 presented with disease recurrence and had their tumors assessed for mutations by NGS sequencing in 
addition to ddPCR analysis
Patients indicated in bold are those that suffered recurrence.
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DISCUSSION
This report describes the results of a retrospective 
assessment of mutant specific ctDNA for patients with 
cutaneous melanoma after removal of a primary lesion 
(n = 30). In three patients with disease recurrence, ctDNA 
was detectable at the time of clinically confirmed disease 
recurrence. In one case, plasma ctDNA detection preceded 
clinical identification of recurrence by an interval of 4 
months. By contrast, ctDNA was not detected at any 
Figure 3: Monitoring ctDNA levels during clinical disease course. The levels of plasma ctDNA for three melanoma patients 
presenting with disease recurrence is represented in relation to the patients’ clinical history in weeks from first primary diagnosis. CtDNA 
concentrations were defined by (A) BRAF K601E (patient 2), (B) NRAS Q12D (patient 6) and (C) BRAF V600E (patient 23) mutant copies. 
The dotted black line indicates the time of resection of primary melanoma or local recurrence. Positive and negative radiological outcomes 
are represented by a solid and dashed blue line, respectively. Surgical procedures are represented by dashed red lines. Solid and dotted 
red lines represent positive and negative exploratory procedures respectively. The shaded area indicates the period during which systemic 
therapy was administered.
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time point in patients with no clinical evidence of disease 
recurrence. 
Although there was variation in the timing of 
plasma collections, which did not necessarily coincide 
with functional imaging, three plasma samples were 
available for each recurring patient before the initiation 
of systemic therapy. In this study, no mutant specific 
ctDNA was detected in any patient prior to detection of 
metastatic disease, however ctDNA was later detected in 
all three patients that presented with disease recurrence 
and subsequently diagnosed with stage IV metastatic 
melanoma. This is in contrast with previous studies in 
stage II and III melanoma [33], uveal melanoma (Beasley), 
breast [28] and colon [27] cancers, which showed that 
ctDNA was detectable in patients with early stage disease.
In patient 23, BRAF V600E mutant ctDNA was 
detectable 4 months prior to metastatic disease being 
clinically evident. Notably, this patient was not undergoing 
routine PET/CT scans due to severe claustrophobia, and 
metastatic disease was discovered during a gastroscopy 
performed to evaluate asymptomatic anemia. Importantly 
however, this suggests that ctDNA may serve as an 
alternative option to those not wishing to undertake 
routine PET/CT scans. 
Although we detected NRAS Q12D mutant ctDNA at 
1.4 copies per mL of plasma at one time point in patient 6, 
we did not detect TERT C228T mutant ctDNA at any time 
point in this patient, although it was detected in the tumor. 
This may be explained by the fact that TERT promoter 
mutations demonstrate lower copy numbers relative to 
other driver mutations [34] (Calapre et al., manuscript 
submitted). Moreover, NRAS mutant ctDNA was not 
detected in the plasma sample collected three weeks prior 
to PET/CT which identified pulmonary metastases, nor 
was it found in the blood sample collected after initiation 
of systemic therapy where the PET/CT scan revealed a 
significant but incomplete response. This highlights 
a limitation in the sensitivity of our ctDNA detection 
approach which may be improved with increasing the 
amount of plasma from which cfDNA is extracted, as 
well as by introducing pre-amplification of cfDNA prior 
to ctDNA quantification. The use of next generation 
sequencing custom panels using unique molecular 
identifiers may also improve sensitivity as well as enable 
monitoring of a large number of mutations. Previously, we 
have shown a correlation between ctDNA and quantitative 
metabolic tumour burden (MTB) derived from PET/CT in 
treatment naïve patients [35]. In addition, future studies 
may further benefit from a correlation between ctDNA 
and MTB in patients undergoing treatment as this will 
further indicate the limit at which ctDNA can be detected 
in patients presenting with distant metastasis(es).
Of importance is the evidence of distant metastatic 
disease in patient 2 almost 9 years after the primary 
melanoma was resected and more than 3 years after 
stage III disease was initially diagnosed which supports 
the evidence that recurrences have been observed many 
years after primary resection [2, 3, 6]. During this time, 
2 PET/CT scans were performed, and it was ultimately 
the colonoscopy which detected metastatic disease and 
prompted the third PET/CT scan which highlights the need 
for improvements in routine monitoring. 
Whilst stage III melanoma patients have a higher 
risk of recurrence than stage I [36, 37], in our cohort 
two of the patients with stage 1 disease and only 1 of 
the patients with stage III disease at time of diagnosis of 
the primary, developed metastatic disease. Furthermore 
tumor thickness has been considered to be an important 
prognostic risk factor for recurrence [38], however here 
we report recurrence from primary tumors of 1.1 mm, 
1.83 mm and 8.3 mm thickness. Previous studies that 
have compared time to recurrence with clinical staging as 
well as host and tumor-dependent variables, have shown 
that older age, gender (male), thin and non-ulcerated 
melanomas are each independently associated with a late 
recurrence (>8 years from time of diagnosis) [7, 8]. In our 
study, we report distant recurrence in one patient with a 
1.1 mm thick non-ulcerated primary 63 weeks after initial 
diagnosis (Figure 3B). Conversely, Faries et al. reported 
tumors less than 1.23 mm and the lack of ulceration to 
each be independently associated with a late recurrence 
which they defined as >10 years from initial diagnosis [7]. 
In one patient with a 1.83mm thick primary, we report a 
local recurrence more than 9 years and metastatic disease 
more than 12 years after initial diagnosis (Figure 3C), 
however Faries et al. reported thicker tumors (2.93 mm) 
to be independently associated with an early recurrence 
(within 3 years of diagnosis) [7]. Whilst we only report 3 
recurrences, the heterogeneity between patient outcomes 
and tumor-dependent variables highlight the challenges 
associated with correctly identifying a subset of patients 
at risk of recurrence from a patient population with an 
expected favorable outcome.
The major limitations of this study are the 
relatively short follow up time and the low number of 
patients analyzed, hence, the low number of observed 
recurrences. Nevertheless, we provide a proof of concept 
indicating that monitoring ctDNA during follow-up 
of melanoma patients after surgery may provide a 
potentially useful clinical test. Our experience confirms 
that ctDNA surveillance provides a supplementary 
method of monitoring patients without the additional 
risk of radiation exposure, invasiveness, and high cost of 
radiological scan, and that ctDNA tests indicate disease 
recurrence at least at the time of clinical confirmation. 
The detection of disease recurrence earlier may provide 
an increased window of opportunity for intervention 
that may positively impact on the patient’s outcomes. 
Furthermore, ctDNA testing may offer an alternative 
option for routine monitoring for patients who are unable, 
for whatever reason, to undergo functional imaging. 
Future prospective studies are needed to demonstrate the 
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utility of ctDNA for routine monitoring of early stage 
melanoma patients. 
In conclusion, this study has provided proof-
of-concept evidence for the prospective and frequent 
monitoring of ctDNA in melanoma patients. However, 
prospective studies and improved assay sensitivity are 
needed before it can be used for monitoring patients after 
resection of their primary for early detection of metastatic 
disease.
MATERIALS AND METHODS
Patient and sample collection
Patient enrolment and study overview are presented 
in Figure 1. We analyzed a group of patients that were 
prospectively accrued into the “Blood Based Biomarkers: 
Prognostic Tools for Melanoma Recurrence” project 
between July 2013 and February 2017. The study was 
approved by the Human Research Ethics Committee of 
Edith Cowan University under reference numbers 11543 
and 13313 and Sir Charles Gairdner Hospital (no.2013-
246). A cohort of 139 melanoma patients (stage 0–III), 
diagnosed and resected in the previous 10 years were 
eligible for enrolment. A blood sample was collected at 
enrolment and then again between 3–25 months thereafter. 
Overall, three cases experienced distant disease recurrence 
during the sample collection period. The BRAF mutation 
status of these three tumors was determined previously 
[38] and by Next Generation Sequencing (NGS) using a 
custom targeted sequencing panel for a third case which 
was found to be BRAF wild-type. A subset of patients 
(n = 27) with no clinical evidence of disease recurrence 
at last follow-up was selected for ctDNA assessment. 
The main criteria for their selection was based on the 
availability of primary tumor mutational data determined 
as part of a previous study [39] in which they were found 
to be positive for at least one of the common melanoma 
mutations (BRAF, NRAS, TERT).
Isolation and quantification of circulating tumor 
DNA from plasma
Blood samples were collected into EDTA vacutainer 
tubes and stored at 4° C. Plasma was separated within 
24 hours by centrifugation at 1600 g for 10 minutes, 
followed by a second centrifugation at 2000 g for 
10 minutes, then stored at −80° C until extraction. Cell 
free DNA (cfDNA) was isolated from 5 mL of plasma 
using the QIAamp Circulating Nucleic Acid Kit (Qiagen) 
as per the manufacturer’s instructions, eluted in 40 µl 
AVE buffer (Qiagen) and stored at –80° C until ctDNA 
quantification. CtDNA was quantified by ddPCR targeting 
the specific mutation found in the patient’s tumor. BRAF 
mutations were detected using in-house primer/probe sets 
[40], NRAS mutations were tested using PrimePCR assays 
(Bio-Rad) and TERT promoter mutations were detected 
using in-house primer/probe sets [41]. Amplifications 
were carried out in a 20 µL reaction mixture containing 
ddPCR Supermix (Bio-Rad), 900 nM primers, 250 nM of 
each probe and 5 ul (for TERT assay) or 8 µL (for BRAF/
NRAS assays) cfDNA. Droplets were generated using 
the Automatic Droplet generator QX200 AutoDG (Bio-
Rad). Droplets were analyzed through a QX200 droplet 
reader (Bio-Rad) and data was analyzed using QuantaSoft 
analysis software (Bio-Rad). For quantification, a 
minimum of 10,000 acceptable droplets was required per 
20 uL reaction. To ensure the accuracy of results, each 
sample was tested minimally in duplicate with each run 
including a non-template control and gDNA from cell lines 
containing the relevant mutation. Samples were deemed 
positive according to criteria previously described [40, 41]. 
In addition, given that 82% of benign melanocytic 
nevi carry BRAF mutations [42], we tested a cohort of 
healthy controls with ≥50 nevi for BRAF V600E and BRAF 
V600K mutant specific cfDNA (Supplementary Table 1). 
None of the samples were found positive, suggesting that 
BRAF V600E/K cfDNA is specific to tumor derived DNA 
and/or nevi do not release sufficient mutated DNA to be 
detectable in plasma using these assays.
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